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ABSTRACT: Tuberculosis (TB) is the leading global cause of death from a single infectious agent. Registered incidence rates are 
low, especially in low-resource countries with weak health systems, due to the disadvantages of current diagnostic techniques. A 
major effort is directed to develop a point-of-care (POC) platform to reduce TB deaths with a prompt and reliable low-cost technique. 
In the frame of the European POCKET Project, a novel POC platform for the direct and non-invasive detection of TB in human urine 
was developed. The photonic sensor is integrated in a disposable cartridge and is based on a highly sensitive Mach-Zehnder Interfer-
ometer (MZI) transducer combined with an on-chip spectral filter. The required elements for the read-out are integrated in an instru-
ment prototype, which allows real-time monitoring and data processing. In this work, the novel POC platform has been employed for 
the direct detection of lipoarabinomannan (LAM), a lipopolysaccharide found in the mycobacterium cell wall. After the optimization 
of several parameters, a limit of detection of 475 pg/mL (27.14 pM) was achieved using a direct immunoassay in undiluted human 
urine in less than 15 minutes. A final validation of the technique was performed using twenty clinical samples from TB patients and 
healthy donors, allowing the detection of TB in people regardless of HIV coinfection. The results show excellent correlation to those 
obtained with standard techniques. These promising results demonstrate the high sensitivity, specificity and applicability of our novel 
POC platform, which could be used during routine check-ups in developing countries.              
Tuberculosis (TB) is a re-emerging infectious disease caused by 
Mycobacterium tuberculosis affecting millions of people 
worldwide. According to the 2017 World Health Organisation 
(WHO) report,1 TB infected 10.4 million people, resulting in 
1.7 million deaths with more than 95% of these cases occurring 
in developing countries. TB is considered the leading fatal in-
fectious agent, surpassing human immunodeficiency virus 
(HIV) and acquired immune deficiency syndrome (AIDS).1 
Two types of TB have been identified: active and latent. In both 
cases, the bacterium is present in the human body. In active TB, 
the bacterium is constantly multiplying, invading diverse or-
gans with a high infective potential. On the other hand, latent 
TB is asymptomatic and the bacterium is inactive without the 
ability to infect others.  
Traditional methods for the detection of active TB include 
culture testing as the current reference standard and sputum 
smear microscopy. However, both of them are imprecise, slow 
and require qualified personnel and laboratory equipment.1–3 
Since 2010, WHO began to recommend the use of a new mo-
lecular assay, GeneXpert (Cepheid, US), based on nucleic acid 
amplification for the detection of M. tuberculosis and for the 
determination of its resistance to rifampicin, the common anti-
biotic employed to treat several infectious diseases, including 
TB.1,4 Although promising at the beginning, GeneXpert has not 
improved the TB screening capabilities as compare to conven-
tional tests; also it incurs infrastructure limitations in develop-
ing countries, as it needs  a controlled temperature environment, 
with the addition of the instrumentation, reagents and cartridges 
costs.1,5 Therefore, there is still an urgent need to develop a 
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highly sensitive and specific point-of-care (POC) platform for 
the rapid diagnosis of TB in low-resource countries; a platform 
that should be cost efficient, user-friendly, non-invasive and re-
quiring minimal biosafety standards.6–8  
Several M. tuberculosis secreted antigens have been de-
scribed as biomarkers in TB, such as lipoarabinomannan 
(LAM), antigen 85 complex (Ag85), ESAT-6, CFP-10 and 
MPT64.7,9–11 These antigens can be used for the direct detection 
of active TB in different biological samples other than sputum, 
such as urine and plasma. Of these, urine is potentially the best 
candidate for a POC analysis as it can be readily obtained from 
children and adults, can be easily stored, has a low infection risk 
during sample collection and does not require a laboratory with 
a high biosafety level.7,12,13  
LAM is a widely known and structurally important 17.5 kDa 
lipopolysaccharide found in mycobacterial cell walls.12,14–16 
When M. tuberculosis is lysed by the host immune system, it is 
filtered by the kidneys and LAM can then be detected in the 
urine.15 Since no human glycosidases are known for the degra-
dation of LAM, an antigen with glycosidic linkages, it is a key 
potential biomarker in urine.13 Several studies have confirmed 
the presence of LAM antigens in the urine of patients with ac-
tive TB12,17 and have found that the amount of LAM in urine is 
correlated with the bacterial burden metabolic activity and rate 
of degradation of the bacteria, and hence allows for a semi-
quantitative assessment of the infection. Also have found that 
LAM antigens play a key role in phagocyte evasion,17 modula-
tion of the host response during infection,18 inhibition of myco-
bacterial antigen processing,17 production of tumour necrosis 
factor17 and growth and pathogenesis of M. tuberculosis19. De-
tection of LAM in urine has several advantages in comparison 
to the conventional techniques. There are ELISA and lateral 
flow tests commercially available for the detection of LAM in 
urine14,20 with adequate diagnostic specificity of 98% to 99%,21 
but unsatisfactory low sensitivity for TB patients who do not 
have HIV. These techniques achieve higher sensitivity (61 - 
67%) for people with less than 50 cluster of differentiation four 
(CD4) cells/µL, who are seriously ill HIV-positive patients, 
than for patients only infected with TB (4 - 8%).14,21 Taking into 
account that TB is the leading cause of death of HIV-positive 
people with more than 40% of incidents worldwide1 and that the 
current methods are not able to detect TB in people without 
HIV,20 effort is necessary to develop new methodologies for TB 
diagnosis in patients with and without HIV in order to reduce 
the number of TB cases and deaths, especially in developing 
countries.  
We present the optimisation and validation of a novel POC 
platform for the direct and non-invasive detection of TB in hu-
man urine. This new POC platform was developed in the frame 
of a European project (www.pocket-proj.eu) and the complete 
description of the new instrument can be found in22. The pho-
tonic sensor chip is based on a highly sensitive Mach-Zehnder 
Interferometer (MZI) transducer combined with an on-chip 
spectral filter (see Figure 1).23 The sensor chip is integrated in a 
disposable polymer microfluidic cartridge. A superluminiscent 
diode (SLED) is used as the light source whereas a CMOS sen-
sor is employed for the signal read-out, both of which are inte-
grated in the instrument prototype. This instrument also incor-
porates a pumping unit and a graphical user interface that allows 
real-time monitoring, data processing and controlling of fluid 
injection into the sensor cartridge. Prior to use, the sensor sur-
face is functionalised with high-quality and selective monoclo-
nal antibodies against LAM. Using this platform, TB detection 
is achieved in undiluted human urine samples in less than 15 
minutes by employing a direct immunoassay. This demon-
strates the high sensitivity, specificity and applicability of our 
platform for TB diagnosis surpassing the existing limitations of 
the current systems. 
Figure 1. Layout of the photonic sensor chip based on Mach-
Zehnder Interferometer transducers and read-out by an on-chip 
spectral filter. Zoom in the sensing area shows a scheme of the bi-
osensing interaction of the anti-LAM/LAM immunoreagents.  
MATERIALS AND METHODS     
Biological samples. Stored urine samples from Tanzania 
used for the validation of TB diagnosis technique. Twenty urine 
samples were used for this study, including 10 healthy donors, 
five TB patients with HIV and five TB patients without HIV. 
All samples were previously analysed using GeneXpert (Ce-
pheid, US) and sputum smear microscopy. 
Prototype instrument. The photonic chip (7.16 x 6.76 mm) 
is fabricated in silicon nitride at wafer-scale in a clean room fa-
cility, integrates six MZI sensors and a reference sensor (see 
Figure 2A). The reference sensor is used to compensate the dis-
persion of the grating couplers, the light source and the on-chip 
spectral filter, resulting in an accuracy increase of the response.  
A complete description of the new POC instrument can be 
found in22. Briefly, a SLED (850 nm) broadband light source is 
coupled to each sensor simultaneously using a separated grating 
coupler. The output of each MZI sensor is connected to an ar-
rayed waveguide grating (AWG) with 30 channels which work 
as on-chip spectral filter. Another separated grating couplers are 
used to couple the light from the 30 output channels of the 
AWG to a CMOS camera which monitors the intensity of the 
different spectral channels simultaneously. 
The photonic chip was placed in a disposable cartridge (75.5 
x 25.5 mm) which is fabricated with cyclic olefin copolymer 
(COC) as shown in Figure 2B. The input and output grating 
couplers are left exposed to avoid variations in the optical path-
ways. A microfluidic channel delivers the sample onto the MZI 
sensing arms. A waste reservoir able to handle a maximum vol-
ume of 1 mL is connected at the end of the fluidic path. The 
cartridge includes three female Luer interfaces to facilitate con-
nections with standard syringes employed for the injection of 
urine samples and the required buffers. The fluidic system in-
cludes a special bubble trap to avoid undesired air bubbles, and 
an optional urine filter (5 µm pore size).  
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Figure 2. (A) Photonic sensor chip. (B) Microfluidic cartridge in-
tegrated with the photonic sensor chip. (C) Microfluidic cartridge 
employing three-syringe system.  
The complete instrument (22 x 22 x 49.30 cm) contains the 
optical system, the pumping units and a touch screen as a user 
interface, as shown in Figure S-1. The sensors are evaluated by 
measuring wavelength shifts due to surface refractive index 
changes.  
The sensorgram of each sensor is graphically displayed in 
real-time providing the user with immediate feedback of the pa-
tient sample diagnosis. Additionally, the interface enables the 
control of the pump speed and time of injection for each syringe 
and bubble trap monitoring. 
Due to the volume limitations of the cartridge waste reservoir 
and the three-syringe configuration in the final POC configura-
tion (Figure 2C), we decided to modify the instrument with an 
in-flow system in order to perform its complete analytical char-
acterisation at the laboratory level, prior to the evaluation of the 
final POC instrument. To include this in-flow system we have 
added: (i) a syringe pump (NewEra, US) with adjustable pump-
ing speed, (ii) a two-position valve (VICI, US) that allows se-
quential loading of the sample loop and injection into the car-
tridge, and (iii) three Teflon caps to provide connections to the 
cartridge female Luer interfaces. One of these caps allows the 
flow of the solution in the cartridge and the other two form a 
vacuum to avoid air bubbles. The evaluation of real samples 
with the new POC platform was performed using both, the in-
flow and the three-syringe configuration. 
Antibody immobilization and direct immunoassay. For 
the detection of LAM, a monoclonal IgG antibody against LAM 
(anti-LAM) was developed within the framework of the project 
by LIONEX GmbH (Germany). The antibody was diluted in 
PBS and immobilised by physical adsorption onto the surface 
of the photonic sensor chip, followed by a blocking step to 
avoid non-specific adsorptions. Milli-Q water was used as the 
running buffer at a flow rate of 10 µL/min.  
Once the immobilisation process was completed, an immu-
noassay was performed which allows the direct detection of 
LAM from the sample. The running buffer was changed to PBS. 
In order to obtain a complete calibration curve, different LAM 
concentrations (1, 10, 50, 100, 250, 500, 750 and 1000 ng/mL) 
were employed. An additive assay was performed by flowing 
successive dilutions of increasing LAM concentrations. 
RESULTS AND DISCUSSION 
Evaluation of the bulk sensitivity. The estimation of the 
bulk sensitivity of the photonic sensor chip to changes in the 
refractive indices of a solution over its sensing area provides a 
preliminary evaluation of the performance and reproducibility 
of our device and the prototype instrument.  
In order to analyse the performance of the sensor chip, differ-
ent solutions of PBS (0.5x, 1x, 2.5x, 5x, 7.5x and 10x), which 
do not chemically modify the sensor surface, were sequentially 
injected providing minute changes in their refractive indices in 
contrast with the milli-Q water employed as running buffer 
(ΔηPBS 0.5x = 1·10
-3 RIU, ΔηPBS 1x = 1.70·10
-3  RIU, ΔηPBS 2.5x = 
4.50·10-3  RIU, ΔηPBS 5x = 8.20·10
-3  RIU, ΔηPBS 7.5x = 1.21·10
-2  
RIU, ΔηPBS 10x = 1.56·10
-2 RIU) (see Figure 3). The refractive 
indices from the different PBS concentrations were determined 
with a digital refractometer (Rudolph Research Analytical, US). 
The noise of the system was very low (0.003 nm) and was de-
termined as the standard deviation of a blank signal in which 
only running buffer was flowing. 
A linear dependence is observed in Figure 3 between the re-
fractive index change and the measured wavelength shift varia-
tion of the sensor output. The calibration for the bulk refractive 
index changes was fitted to a linear model (R2 = 0.99), resulting 
in a limit of detection (LOD) as low as 3 · 10-6 RIU. This eval-
uation was repeated using different sensor cartridges, and re-
sulted in the same LOD, demonstrating in this way the excellent 
performance and reproducibility of the sensor chips and the 
POC platform.  
Production of anti-LAM and LAM. The proprietary mouse 
anti-LAM IgG is specific monoclonal antibodies to mycobacte-
rial LAM with high affinity towards M. tuberculosis LAM.   
 
Figure 3. Calibration curve of the sensor chips by flowing solutions 
of PBS with different refractive indices. The top of each bulk 
change specifies the ∆η that is evaluated (η[PBS] – ηH2O). 
The antibody was purified from defined hybridoma cells cul-
ture by affinity chromatography. The quantity of antibody was 
determined using the Lowry protein assay and the purity of the 
antibody was analysed using SDS gel electrophoresis, western 
blotting, Tapestation and exclusion chromatography. The anti-
body preparation purity was determined to be 95% pure. Spe-
cific antigen-antibody binding was determined by western blot 
utilising purified M. tuberculosis LAM (LIONEX, Germany) 
(Figure S-2) and ELISA. 
Furthermore Bio-Layer Interferometry (BLI) was used for 
binding affinity measurement of the purified antibody to the pu-
rified M. tuberculosis LAM. Our data reveals that anti-LAM 
IgG has low KD values (below 10-8 M) which indicate that this 
antibody possess high affinity towards mycobacterial LAM 
(Figure S-3 and Table S-1). The affinity values support the high 
specificity and affinity of this antibody to LAM molecules. 
Label-free immunoassay for LAM detection. A standard 
physical adsorption functionalisation in which the antibody is 
immobilised via hydrophobic and electrostatic interactions was 
selected for our new diagnostic platform.24 Physical adsorption 
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involves two steps: the immobilisation of the antibody by elec-
trostatic interactions and the blocking of the free sites to prevent 
non-specific adsorptions.  
To pursue the biosensing evaluation, an optimisation with 
buffer is advised before using complex matrices, such as urine. 
The evaluation in buffer will allow us to study the performance 
of the biosensor platform for the specific TB biomarker without 
the interference of other proteins or compounds also present in 
urine. 
Different immobilisation parameters must be optimised for 
the LAM detection in buffer. In order to provide a good anti-
LAM density with enough accessibility to LAM and to guaran-
tee a suitable surface coverage for minimising non-specific ad-
sorptions, various concentrations of the antibody and BSA, as 
blocking agent, were tested to improve the immobilisation per-
formance. Each antibody concentration, ranging from 10 to 100 
µg/mL, was evaluated at fixed conditions for pump speed (10 
µL/min) and time (30 min). The surface coverage was analysed 
from the immobilisation signal. Immobilisation signals showed 
an increasing tendency with increasing antibody concentrations 
(data not shown). As antibody concentrations above 50 µg/mL 
showed a similar signal, this means that the sensor surface was 
almost covered with 50 µg/mL of the antibody. After the anti-
body immobilisation, the same procedure was followed for the 
blocking step using different concentrations of BSA  (from 1 to 
10 mg/mL) and analysing the detection signal of a non-specific 
protein (data not shown). A PBS solution with 10 mg/mL of 
BSA was the one that blocks the remaining free sensor surface 
areas and avoids non-specific adsorptions.  
Using the optimised protocol, an antibody solution (50 
µg/mL) in PBS was injected followed by a BSA solution (10 
mg/mL). Milli-Q water was employed as running buffer for the 
immobilisation step The immobilisation step shows high repro-
ducibility between different sensor cartridges (Coefficient of 
Variation (CV): 5%). The running buffer was changed to PBS 
once the immobilisation process was finished and the target de-
tection was then carried out. Target LAM samples were dis-
solved in PBS at concentrations ranging from 1 to 1000 ng/mL 
and injected into the system. All experiments with LAM in 
buffer were done by triplicate. 
An example of real-time LAM detection (250 ng/mL)   
 
 
Figure 4. (A) Real-time sensogram showing the detection of 250 ng/mL of LAM in buffer. (B) Sensograms showing the LAM detection at 
different concentrations (from 1 to 1000 ng/mL of BSA protein) in buffer. (C) Calibration curve obtained for different LAM concentrations 
in buffer. Solid line corresponds to the one-site specific binding fit. All data show mean ± SD of triplicate measurements.
with the POC instrument is shown in Figure 4A. A simultane-
ous good response for all of the sensors contained in the same 
photonic sensor chip was observed. 
As antibodies are not covalently attached to the sensor sur-
face, it was not possible to regenerate the biosurface. For this 
reason, we have employed an additive immunoassay.  
Successive dilutions of increasing LAM concentrations were 
injected in order to estimate the sensitivity, as shown in Figure 
4B. For all of the concentrations evaluated, a clear sensor re-
sponse was obtained. As expected with an additive assay, the 
antibody reaches a saturation level and loses its ability to detect 
more LAM, explaining the reduced sensor signal. For example, 
Figure 4B shows a higher LAM signal response for 250 ng/mL 
than for 1000 ng/mL.  
The selectivity of the biosensor was tested under the ex-
plained conditions for LAM detection, monitoring the wave-
length shift after the injection of 1000 ng/mL of BSA protein, a 
non-specific protein for the immobilised antibody. As observed 
in Figure 4B (control), BSA protein leads to a negligible re-
sponse of the biosensor.  
A calibration curve of triplicates for LAM detection in buffer 
was plotted in Figure 4C, resulting in a LOD of 956 pg/mL 
equivalent to 54.63 pM (R2 = 0.98), revealing the excellent sen-
sitivity of the sensors and the selectivity of the antibodies 
against LAM, and overall indicating the good performance of 
the photonic chip and the prototype instrument. 
For the evaluation of the reproducibility between sensors, the 
standard deviation was calculated for nine different detection 
signals by triplicate, obtaining a mean value of 40 pm. This re-
sult demonstrates that the variability between sensors is negli-
gible. 
LAM analysis in spiked urine samples. The main goal for 
a sensor applied to clinical diagnosis is the ability to detect a 
biomarker or a panel of biomarkers associated with the disease 
directly in human biological fluids, preferably obtained using a 
non-invasive technique. For this reason, the next step in our 
study was the evaluation of LAM directly in human urine. Urine 
is an ideal candidate for a POC platform due to its advantages 
in obtainment and storage.  
We directly analysed LAM in real human urine samples, 
which is especially complex due to the undesired non-specific 
adsorption of different urine components. Several blocking 
agents can be employed to avoid or greatly decrease non-spe-
cific adsorption on the sensor surface. Previous studies have 
demonstrated that coating of the sensor surface with PLL-g-
PEG and the presence of surfactant agent Tween 20 in the de-
tection buffer, minimises the background signal produced by 
undiluted urine.25–27 Based on this, we have studied the effect of 
different concentrations of blocking agents in order to reduce 
non-specific adsorption when flowing urine from a healthy pa-
tient over the sensors were we have previously immobilised the 
anti-LAM antibody: (i) 10 mg/mL of BSA, (ii) 0.5 mg/mL of 
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PLL-g-PEG and (iii) 0.75 mg/mL of PLL-g-PEG and 10 mg/mL 
of BSA. First, an undiluted urine sample from a healthy donor 
was injected on the surface blocked with 10 mg/mL of BSA and 
resulted in a background signal of 1.27 nm. Second, using 0.5 
mg/mL of PLL-g-PEG for the surface blocking, we observed a 
strong reduction of non-specific binding of undiluted urine with 
respect to BSA solution, but we cannot consider it as a negligi-
ble signal. In order to avoid this small signal, a combination of 
0.75 mg/mL of PLL-g-PEG and 10 mg/mL of BSA was used to 
minimise non-specific adsorption between the urine compo-
nents and the sensor surface to 80 pm. Thus, we will adopt this 
strategy for future evaluations of real urine samples and use 
PBS with 0.5% of Tween 20 as the running buffer for the eval-
uation of urine samples. When monitoring undiluted urine in 
real-time, a peak can be observed when the sample starts to flow 
in the sensing area (see Figure 5B), which we attribute to the 
use of PBST 0.5% as running buffer. 
Diluted urine and undiluted urine were evaluated in order to 
observe possible interferences of the urine matrix in the additive 
assay. Spiked urine samples with different LAM concentrations 
were diluted 1:1 in PBS or injected directly without a pre-treat-
ment onto the sensor. Figure 5 illustrates the different LAM 
concentrations in diluted and undiluted urine. Injection of urine 
from a healthy donor was performed, resulting in no back-
ground signal (see Figure 5) and confirming the absence of non-
specific adsorptions of urine components.  
 
Figure 5. Sensograms showing the LAM detection at different con-
centrations (from 1 to 1000 ng/mL) and control in (A) diluted and 
(B) undiluted urine. 
A calibration curve of triplicates for LAM-spiked undiluted 
and diluted urine was plotted in Figure 6, resulting in a LOD of 
731 pg/mL (41.77 pM; R2 = 0.97) and 475 pg/mL (27.14 pM; 
R2 = 0.92), respectively. With reproducible and repetitive re-
sults, the curve of LAM-spiked undiluted urine showed higher 
sensitivity than in buffer and diluted urine (see Figure 6), sug-
gesting that urine components create a more favourable envi-
ronment for the antibody-antigen interaction.  
 
Figure 6. Calibration curves obtained for different LAM concen-
trations in buffer, diluted urine and undiluted urine. Solid line cor-
responds to the one-site specific binding fit of every curve. All data 
show mean ± standard deviation of triplicate measurements.  
 
The LOD in undiluted urine obtained with our new POC plat-
form is better than those achieved using commercial lateral flow 
tests (LOD 105 – 106 pM) and conventional ELISAs (LOD 
1.83·105 pM), using different antibodies and immunoassay for-
mats.28–30 
The results confirmed the high sensitivity and specificity of 
our methodology, as well as the robustness of not only the anti-
bodies but also the photonic sensor chips and the prototype in-
strument. In case that a positive signal is observed with this 
methodology, it would presumably represent the specific recog-
nition of LAM by the antibodies immobilised on the sensor sur-
face. 
Validation with real urine samples. With the promising 
previous results in spiked urine, we were able to validate the 
prototype using a direct assay without the need of any pre-treat-
ment of the human urine samples to be analysed. There are 
some parameters, such as pH and the concentration of different 
urine components, which can strongly vary between patients 
and which can have an effect in the evaluation.   
With the optimal conditions previously selected for the eval-
uation of undiluted urine, we applied the POC platform to study 
the presence of LAM in the urine of 10 patients with confirmed 
TB from Tanzania and 10 healthy patients from Tanzania and 
Spain. The Tanzania samples were collected from hospitals and 
directly observed treatment short course (DOTS) centers,31 
while the Spain samples were donated by volunteers.  
Non-treated and undiluted real urine samples were directly 
flowed over the sensor chip using the in-flow system. Signals 
were monitored in real-time and converted into positive or neg-
ative TB diagnosis depending on the obtained LAM signal, as 
shown in Figure 7A. Based on the shifts from the optimisation 
process, patients were determined to be TB positive if the LAM 
signal was higher than 90 pm. Through evaluation of twenty 
real urine samples and taking into account this threshold, only 
one sample was identified as a false positive (see Figure 8). In 
our case, it is not important to determine the LAM concentra-
tion in urine, due to the fact that LAM is a cell wall component 
of M. tuberculosis and can only be present in the urine of those 
infected with the pathogenic bacteria.  
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Positive results with the in-flow system allow the evaluation 
of the same real samples using the final configuration of the 
POC prototype which does not use the external pumps but em-
ploys a three-syringe system. With this configuration, two of 
the syringes contained PBST 0.5% and the other one the urine 
sample (150 L). An example of a real-time signal for the same 
samples as for the in-flow system is shown in Figure 7B. The 
resulted signal for healthy urine returns back to the baseline (see 
Figure 7B). 
A comparison between both systems for the evaluation of two 
specific samples is shown in Figure 7. With both systems we 
cannot observe any significance difference in the absolute value 
of the obtained wavelength shift variation. This can also be ob-
served in Figure 8 for the twenty urine samples analysed. The 
main difference between both systems was observed for Patient 
4 (see Figure 8), who was the only false positive observed in 
our study when using the in-flow system. Taking account all 
these results, we can corroborate the high reproducibility and 
diagnosis capacity of our methodology.  
 
 
Figure 7. Real-time sensograms for the comparison of two real 
urine samples using (a) three-syringe and (B) in-flow systems.  
One of the disadvantages of the current LAM detection meth-
ods in urine is that they are not able to detect TB in people with-
out HIV. However, with our novel POC platform, the time to 
result is only 15 minutes for the classification of patients as 
healthy or infected, regardless of HIV coinfection, as shown in 
Figure 8.  
Figure 8. Bar plot of the wavelength shift signals obtained from the 
analysis of twenty urine samples from healthy and TB patients with 
and without HIV using two different systems for the fluid injection. 
 Current meth-
ods 
POC prototype 
P HIV TB pH T1 T2 Three-
syringe 
In-
flow 
11 0 Yes 8 N/A N/A Yes Yes 
12 1 Yes 8 N/A N/A Yes Yes 
13 1 Yes 8 N/A N/A Yes Yes 
14 1 Yes 7 Yes No Yes Yes 
15 0 Yes 7 Yes Yes Yes Yes 
16 0 Yes 7 Yes Yes Yes Yes 
17 0 Yes 8 Yes Yes Yes Yes 
18 1 Yes 9 Yes Yes Yes Yes 
19 1 Yes 8 Yes Yes Yes Yes 
20 0 No 6 N/A N/A Yes Yes 
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Black arrow shows the threshold to classify patients as healthy or 
infected.  
Table 1 and 2 list and compare the results of the analysis ob-
tained with the novel POC and with current techniques such as 
GeneXpert and sputum smear microscopy. For each patient, the 
values of pH, HIV status and current TB diagnosis are reported. 
Results obtained with our platform show a good correlation to 
those obtained with the current methods as observed when com-
pared the data in both tables. As illustrated in Figure 8 and Ta-
bles 1 and 2, out of the 20 real urine samples analysed by dupli-
cate, 10 samples were true positive, 9 samples were true nega-
tive and when using the in-flow approach, only one sample was 
a false positive. Therefore, the validation of the novel POC plat-
form using the final configuration with three-syringe showed a 
sensitivity of 100%, a specificity of 100% and an area under the 
curve (AUC) of 1  as calculated by a ROC curve analysis (Fig-
ure S-4). This analysis was also carried out for the in-flow sys-
tem and both systems together (Figure S-5 and S-6).  
Table 1. Evaluation of urine samples from healthy volunteers 
with the POC prototype. 
 POC prototype 
Healthy 
donors 
pH Three-sy-
ringe 
In-
flow 
1 8 No No 
2 8 No No 
3 8 No No 
4 7 No Yes 
5 7 No No 
6 7 No No 
7 8 No No 
8 9 No No 
9 8 No No 
10 6 No No 
Table 2. Evaluation of urine samples from patients with con-
firmed TB using current methodologies (GeneXpert and Mi-
croscopy) in comparison with the POC prototype.  
P: patients; HIV: HIV status; TB: TB diagnosis; T1: GeneXpert; T2: Microscopy; 
CONCLUSIONS 
We have developed a novel POC platform for the detection 
of a cell wall component of M. tuberculosis in undiluted urine 
based on a highly sensitive MZI sensor chip integrated in a pol-
ymer microfluidic cartridge. The strategy consists of a direct 
immunoassay for the label-free LAM detection in unprocessed 
urine in less than 15 minutes. Several parameters have been op-
timised, reaching a limit of detection as low as 475 pg/mL 
(27.14 pM) for the direct detection in spiked urine samples and 
corroborating the excellent selectivity and sensitivity of the pro-
duced antibodies. The validation of the methodology with clin-
ical samples from TB patients and healthy donor samples al-
lows the detection of TB in people with and without HIV coin-
fection and the results show excellent correlation to those ob-
tained with GeneXpert, and sputum microscopy techniques. 
The platform has shown a high sensitivity (100%) and specific-
ity (100%) in comparison with rapid tests commercially availa-
ble for TB detection. The diagnosis of people only infected with 
TB has not been possible with the current rapid tests on the mar-
ket, providing more advantages to our POC instrument. The ad-
vantages added to our instrument (low cost, user friendliness, 
results in 15 minutes, no requirement for qualified personnel for 
operation and no need of special laboratory infrastructure) make 
this POC platform an outstanding candidate for in-situ use in 
primary doctor’s office and patient’s bedsides. We therefore 
demonstrated the high sensitivity, specificity and applicability 
of our platform, which could be used during routine check-ups 
in developing countries.   
As the instrument is designed for the simultaneous detection 
of a panel of six different biomarkers, this open the door for the 
use of our POC platform for the fast detection of different dis-
eases, such as diabetes, cancer, HIV, stroke, heart diseases, de-
mentias diseases, malaria, hepatitis A, respiratory infections, 
and kidney diseases, among others. 
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